OX2R Agonist Pipeline: Narcolepsy & Hypersomnia — PatSnap Eureka
OX2R Agonist Pipeline: Narcolepsy & Idiopathic Hypersomnia
Orexin type 2 receptor (OX2R) agonism has emerged as the leading disease-mechanistic strategy for narcolepsy type 1 and idiopathic hypersomnia. Explore the patent landscape spanning Takeda, Sumitomo Pharma, Lundbeck, and beyond — powered by PatSnap Eureka.
Why OX2R Agonism Is the Mechanistic Approach for Narcolepsy
Narcolepsy type 1 (NT1) is driven by autoimmune destruction of hypothalamic orexin-producing neurons. Both orexin A and orexin B are produced exclusively in neurons of the lateral hypothalamus and surrounding regions, acting as endogenous ligands of G protein-coupled receptors OX1R and OX2R. Multiple Takeda filings in this dataset make the specific pharmacological argument that OX2R — rather than OX1R — is the primary receptor subtype governing arousal maintenance, supported by OX2R knockout mouse studies demonstrating impaired wakefulness.
Intracerebroventricular orexin peptide administration reverses narcolepsy-like phenotypes in transgenic mice with degenerated orexin neurons. A Takeda patent filing specifically notes that orexin-B shows high selectivity for OX2R relative to OX1R, supporting OX2R-selective agonism as the preferred mechanistic approach. OX2R is described as a Gq/Gs-coupled GPCR expressed broadly in the arousal network, with higher brain-region density than OX1R.
Beyond narcolepsy and idiopathic hypersomnia, retrieved results from Centessa Pharmaceuticals (Orexia) note that orexin receptor agonism is also implicated in neurodegenerative disorders, rare genetic disorders, metabolic syndrome, and coma emergence. PatSnap's life sciences intelligence platform enables teams to track this expanding indication landscape in real time.
According to the World Health Organization, sleep disorders affect hundreds of millions globally, underscoring the unmet medical need that OX2R agonists aim to address. The PatSnap Analytics suite provides competitive patent landscape analysis for teams monitoring this space.
OX2R Agonist Scaffold Landscape & Filing Activity
Across more than 30 retrieved patent records, six distinct scaffold modalities compete for OX2R agonist space — with heterocyclic small molecules and urea derivatives dominating filing volume.
OX2R Agonist Scaffold Modalities — Filing Volume
Heterocyclic small molecules account for more than 20 filings; urea series (cycloalkyl + phenyl) contribute ~10; cyclic guanidinyl, bicycloamine, spiro-macrocyclic, and peptide series represent earlier or emerging entries.
Primary Indications Claimed Across OX2R Agonist Patents
Narcolepsy (NT1) dominates indication claims; idiopathic hypersomnia and EDS are explicitly cited alongside; sleep apnea and broader neurological indications represent emerging scope.
Six Distinct Modalities Competing for OX2R Agonist Space
From piperidines to peptides, the OX2R agonist pipeline spans a diverse chemical landscape. Each scaffold series represents independent IP with distinct assignees and prosecution strategies.
Heterocyclic Small Molecules — Piperidines, Pyrroloimidazoles & Macrocycles
The largest cluster in this dataset — more than 20 patent filings — covers Takeda's heterocyclic small-molecule OX2R agonists. Sub-series include substituted piperidines (WO 2017, EP 2018, US 2020), N-heterocyclic and pyrrolo[1,2-c]imidazole derivatives (US 2026, WO 2024/2025), and macrocyclic/spiro-macrocyclic heterocycles (WO 2024, US 2024, IN 2025). Jurisdictions span WO, US, EP, CA, JP, BR, IN, AR, CO, ES, ID, PH, NZ, TW — signalling active, multi-generational medicinal chemistry campaigns.
20+ filings · Multi-jurisdictional · Preclinical → translationalUrea Scaffolds — Cycloalkyl Urea & Phenyl Urea Derivatives
Sumitomo Pharma has developed a parallel programme centred on urea-skeleton compounds. Cycloalkyl urea derivatives are filed across EP, US, CA, AU, IN, MX, BR from 2021 through 2025. A related phenyl urea series (NZ, MX, EP, 2022–2024) represents a chemically distinct sub-series. Retrieved abstracts consistently claim OX2R-mediated therapeutic and prophylactic effects in narcolepsy, idiopathic hypersomnia, hypersomnia, and sleep apnea. Multi-jurisdictional filing breadth signals active prosecution preparatory to clinical advancement.
~10 filings · Distinct from Takeda scaffolds · IH & NT1 claimedBicycloamine Carboxamide Derivatives — Fused-Ring Skeletons
A third chemically distinct Sumitomo series — bicycloamine carboxamide derivatives with fused-ring skeletons — appears in CA, EP, AU, and BR filings from 2024–2025. These compounds act specifically via OX2R for treatment of narcolepsy, idiopathic hypersomnia, and sleep apnea, representing a more structurally differentiated approach relative to the urea series. The PatSnap Analytics platform enables rapid freedom-to-operate analysis across these overlapping scaffold families.
~4 filings · Structurally differentiated · NT1, IH, sleep apneaCyclic Guanidinyl Small-Molecule OX2R Agonists
An academically-originated programme from the University of Texas System (Board of Regents), associated with inventor Masashi Yanagisawa, covers non-peptidic cyclic guanidinyl OX2R agonists. Filed from 2012 through 2021 (WO, US, AU, JP, MX), these compounds are described as blood-brain barrier-penetrant, orally active small molecules capable of enhancing wakefulness, reducing diet-induced adiposity, and facilitating recovery from general anesthesia through selective OX2R agonism. This represents foundational academic IP in the field.
~5 filings · BBB-penetrant · Orally active · Academic originSpiro-Macrocyclic OX2R Agonists
A distinct spiro-macrocyclic scaffold for OX2R agonism appears in a 2026 (BR) patent filing from H. Lundbeck A/S, representing the first entry of a major CNS pharmaceutical company into the OX2R agonist space within this dataset. The filing describes spiro-macrocyclic compounds of general formula (I) as OX2R agonists. Spiro-macrocyclic architectures may offer improved receptor selectivity or CNS pharmacokinetic properties relative to classical heterocyclic small molecules, though clinical viability remains undemonstrated in the retrieved data.
1 filing · CNS-focused entrant · Structural differentiationPeptide-Based Orexin Receptor Agonists
A single retrieved patent filing from Centessa Pharmaceuticals (Orexia) Limited (WO 2024) describes engineered peptide derivatives — 23-amino-acid sequences related to orexin neuropeptides — as orexin receptor agonists. The disclosure targets narcolepsy, hypersomnia disorders, neurodegenerative disorders, rare genetic disorders, metabolic syndrome, and other indications, representing a peptide-based modality divergence from the dominant small-molecule field. As noted by NIH, peptide therapeutics face CNS penetration and metabolic stability challenges that are not addressed in the retrieved abstract.
1 filing · Non-small-molecule · Broad indication scopeOX2R Agonist Assignee & Programme Landscape
Patent activity in this dataset is dominated by two Japanese pharmaceutical companies and one academic institution. The table below maps each assignee to their scaffold focus, jurisdictions, and development signals.
| Assignee | Scaffold Series | Key Jurisdictions | Filing Range | Primary Indications | Translational Signal |
|---|---|---|---|---|---|
| Takeda Pharmaceutical | Piperidines, heterocycles, macrocycles, pyrroloimidazoles | WO, US, EP, CA, JP, BR, IN, AR, CO, ES, ID, PH, NZ, TW | 2017–2026 | NT1 IH EDS | Dosing/PK methodology patents; human NT1 language; MNC framework |
| Sumitomo Pharma | Cycloalkyl urea, phenyl urea, bicycloamine carboxamide | EP, US, CA, AU, MX, IN, BR, NZ | 2021–2025 | NT1 IH Sleep Apnea | Multi-jurisdictional prosecution; distinct scaffolds from Takeda |
| Univ. of Texas / Yanagisawa | Cyclic guanidinyl non-peptidic OX2R agonists | WO, US, AU, JP, MX | 2012–2021 | Narcolepsy Wakefulness | BBB-penetrant, orally active; foundational academic IP |
Track New OX2R Agonist Filings as They Publish
PatSnap Eureka monitors 180M+ patent records across 100+ jurisdictions in real time. Set alerts for OX2R, narcolepsy, and competitor assignees.
The Non-Awakening Concentration Framework — Takeda's Key Translational Signal
The most advanced translational signals in this dataset come from a cluster of Takeda dosing patents (WO 2024, CA 2024, IN 2025, WO 2025, TW 2024, CN 2025, BR 2025) that define a specific pharmacokinetic dosing strategy: the concept of "non-awakening concentration" (MNC) — the maximum non-awakening blood plasma concentration of OX2R agonist.
These filings disclose compositions and methods for maintaining OX2R agonist plasma concentrations at or below the MNC during non-waking hours, and a "wake-promoting" plasma concentration maintained during a portion of waking hours, with sub-MNC levels for the remainder of a 24-hour period. The 2025 Takeda WO filing explicitly claims maintaining wake-promoting concentrations "during a portion of waking hours of a twenty-four-hour period" — signalling recognition that continuous OX2R agonism may interfere with night-time sleep architecture.
A Takeda WO 2022 record covering the specific compound methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)-piperidine-1-carboxylate explicitly covers treatment of idiopathic hypersomnia and excessive daytime sleepiness "in a human in need thereof," using human-directed clinical language that signals at least Phase 1 preparedness.
A further Takeda CN filing (2025) describes OX2R agonist use for improving respiratory function during sleep (sleep apnea), with preclinical data from rat medullary slice and brainstem-spinal cord preparations showing activation of pre-Bötzinger complex neurons and phrenic motor neurons — supporting neurophysiological mechanism characterisation for clinical translation. The PatSnap customer network includes leading pharma teams tracking exactly these translational inflection points. The European Medicines Agency provides regulatory context for CNS drug development pathways relevant to these programmes.
Four Strategic Implications for Drug Developers & IP Teams
Derived from the retrieved patent and literature landscape — actionable intelligence for R&D strategy, competitive monitoring, and business development.
Takeda Holds Dominant IP Breadth in This Dataset
With multiple scaffold series (piperidines, heterocycles, macrocycles, pyrroloimidazoles), dedicated dosing-methodology patents, and filings specifically referencing idiopathic hypersomnia and human NT1 subjects, Takeda's portfolio signals the most advanced and diversified OX2R agonist programme in the retrieved dataset. IP strategists assessing freedom-to-operate or partnership opportunities should treat the Takeda portfolio as the primary blocking landscape.
Sumitomo Presents a Substantive Competing Programme
The parallel Sumitomo urea and bicycloamine series across comparable global jurisdictions represent a competing small-molecule OX2R agonist programme with distinct chemical scaffolds, offering potential differentiation or partnering opportunities — particularly for indications where Takeda's substituted piperidine series does not yet have IP coverage. PatSnap's chemical intelligence tools support scaffold comparison and FTO analysis.
Beyond NT1: Emerging IP Directions in the OX2R Agonist Space
Retrieved results point to four distinct emerging directions expanding the OX2R agonist competitive landscape beyond the established Takeda/Sumitomo axis.
Circadian Pharmacokinetic Optimisation
The most distinctive emerging direction in retrieved results is temporally differentiated dosing schedules — delivering wake-promoting plasma concentrations during waking hours and sub-MNC concentrations during sleep. The 2025 Takeda WO filing explicitly claims maintaining wake-promoting concentrations "during a portion of waking hours of a twenty-four-hour period" and sub-threshold concentrations for the remainder. This signals that circadian pharmacokinetic optimisation is a key development challenge and IP differentiation vector.
7 dosing patents filed 2024–2025OX2R Agonism for Sleep Apnea
Retrieved CN filings from Takeda (2025) disclose OX2R agonist activity on brainstem respiratory circuits — pre-Bötzinger complex and phrenic motor neurons — suggesting that signals from this dataset point toward OX2R agonism as a respiratory neuromodulator for sleep apnea. This broadens the indicated disease scope beyond NT1 and represents a mechanistically distinct application of OX2R agonism. The PatSnap platform enables cross-indication patent monitoring for teams tracking this expansion.
Preclinical brainstem data · Rat medullary slice modelsSpiro-Macrocyclic Architectures
The Lundbeck BR 2026 filing on OX2R spiromacrocyclic agonists signals structural diversification toward constrained macrocycles, which may offer improved receptor selectivity or CNS PK properties relative to classical heterocyclic small molecules. This represents a relatively recent entry into this space by a major CNS-focused pharmaceutical company, and early-stage drug developers may find freedom-to-operate in this structurally differentiated modality, though clinical viability remains undemonstrated in the retrieved data.
New entrant · CNS-focused · 2026 filingPrepro-Orexin Peptide Fragments as BDNF Inducers
A Japanese academic patent (Toyama University, JP 2023) describes C-terminal prepro-orexin fragments as BDNF expression enhancers in brain cells, representing an indirect orexinergic approach to neuroprotection. This direction, if validated, could complement direct OX2R agonism in neurodegenerative comorbidities — representing a mechanistically orthogonal but potentially synergistic development path to the dominant small-molecule OX2R agonist programmes. According to NCBI/PubMed, BDNF induction is an active area of CNS neuroprotection research.
Academic · Indirect mechanism · Neuroprotection angleOX2R Agonist Pipeline in Narcolepsy & Hypersomnia — Key Questions Answered
OX2R (orexin type 2 receptor) is a Gq/Gs-coupled GPCR expressed broadly in the arousal network. Multiple Takeda filings note that OX2R is critical for wake maintenance, supported by OX2R knockout mouse phenotypes showing narcolepsy-like symptoms. Narcolepsy type 1 arises from the selective loss of orexin-producing neurons, resulting in orexin deficiency at OX2R, making OX2R agonism a disease-mechanistic therapeutic strategy.
Takeda Pharmaceutical Company Limited is the highest-volume assignee in this dataset, with at least 25 distinct patent records across jurisdictions including WO, US, EP, CA, JP, BR, IN, AR, CO, ES, ID, PH, NZ, TW. Sumitomo Pharma Co., Ltd. appears with approximately 10 patent records across cycloalkyl urea, phenyl urea, and bicycloamine carboxamide series. H. Lundbeck A/S and Centessa Pharmaceuticals (Orexia) Limited represent newer entrants with spiro-macrocyclic and peptide-based approaches respectively.
Retrieved results cover multiple scaffold families: substituted piperidines, N-heterocyclic and pyrrolo[1,2-c]imidazole derivatives, macrocyclic heterocycles, cycloalkyl urea derivatives, phenyl urea derivatives, bicycloamine carboxamide derivatives, spiro-macrocyclic compounds, cyclic guanidinyl small molecules, and peptide derivatives based on 23-amino-acid sequences related to orexin neuropeptides.
Takeda's dosing patents (WO 2024, CA 2024, IN 2025, WO 2025, TW 2024, CN 2025, BR 2025) define the concept of 'non-awakening concentration' or 'maximum non-awakening blood plasma concentration' (MNC) of OX2R agonist. These filings disclose compositions and methods for maintaining OX2R agonist plasma concentrations at or below the MNC during non-waking hours, and a 'wake-promoting' plasma concentration maintained during a portion of waking hours, with sub-MNC levels for the remainder of a 24-hour period.
While retrieved results from Takeda and Sumitomo cite idiopathic hypersomnia and hypersomnia broadly alongside narcolepsy, the clinical methodology patents focus primarily on NT1. A Takeda WO 2022 record covering a specific piperidine compound explicitly covers treatment of idiopathic hypersomnia and excessive daytime sleepiness 'in a human in need thereof.' This suggests an underexplored clinical development opportunity for IH-specific OX2R agonist trials.
Retrieved CN filings from Takeda (2025) disclose OX2R agonist activity on brainstem respiratory circuits (pre-Botzinger complex, phrenic motor neurons), suggesting signals toward OX2R agonism as a respiratory neuromodulator for sleep apnea. Centessa Pharmaceuticals notes orexin receptor agonism is also implicated in neurodegenerative disorders, rare genetic disorders, metabolic syndrome, and coma emergence. A Toyama University patent describes C-terminal prepro-orexin fragments as BDNF expression enhancers in brain cells.
Still have questions? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka About OX2RAccelerate Your OX2R Drug Discovery Intelligence
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D — from patent landscape analysis to competitive monitoring across narcolepsy, idiopathic hypersomnia, and sleep disorders.
References
- Heterocyclic compound that has agonist activity of the type 2 orexin receptor — Takeda Pharmaceutical Company Limited, 2025, AR [Patent]
- Bicycloamine carboxamide derivative — Sumitomo Pharma Co., Ltd., 2025, CA [Patent]
- Bicycloamine carboxamide derivative — Sumitomo Pharma Co., Ltd., 2025, EP [Patent]
- Bicycloamine carboxamide derivative — Sumitomo Pharma Co., Ltd., 2024, AU [Patent]
- Dosing of orexin type 2 receptor agonists — Takeda Pharmaceutical Company Limited, 2024, CA [Patent]
- Substituted piperidine compound as orexin type 2 agonist for the treatment of narcolepsy — Takeda Pharmaceutical Company Limited, 2024, EP [Patent]
- Heterocyclic compound — Takeda Pharmaceutical Company Limited, 2025, WO [Patent]
- Method for treating type 1 narcolepsy in a human in need of it — Takeda Pharmaceutical Company Limited, 2025, BR [Patent]
- Macrocyclic heterocycle compounds and use thereof — Takeda Pharmaceutical Company Limited, 2025, IN [Patent]
- Macrocyclic heterocycle compounds and use thereof — Takeda Pharmaceutical Company Limited, 2024, WO [Patent]
- Heterocyclic compound — Takeda Pharmaceutical Company Limited, 2024, WO [Patent]
- Heterocyclic compound and use thereof — Takeda Pharmaceutical Company Limited, 2024, WO [Patent]
- Derivative of bicycloamine carboxamide — Sumitomo Pharma Co., Ltd., 2025, BR [Patent]
- Cycloalkyl urea derivative — Sumitomo Pharma Co., Ltd., 2022, EP [Patent]
- Cycloalkylurea derivative — Sumitomo Dainippon Pharma Co., Ltd., 2024, US [Patent]
- Cycloalkylurea derivative — Sumitomo Pharma Co., Ltd., 2025, US [Patent]
- Phenyl urea derivative — Sumitomo Pharma Co., Ltd., 2022, NZ [Patent]
- Phenyl urea derivative — Sumitomo Pharma Co., Ltd., 2024, EP [Patent]
- Substituted piperidine compound and use thereof — Takeda Pharmaceutical Company Limited, 2020, US [Patent]
- Substituted piperidine compound and use thereof — Takeda Pharmaceutical Company Limited, 2018, EP [Patent]
- Substituted piperidine compound and use thereof — Takeda Pharmaceutical Company Limited, 2017, WO [Patent]
- Substituted piperidine compound and use thereof — Takeda Pharmaceutical Company Limited, 2024, CA [Patent]
- Pyrrolo[1,2-c]imidazole derivatives as orexin type 2 receptor agonists and methods of use thereof — Takeda Pharmaceutical Company Limited, 2026, US [Patent]
- Heterocyclic compound — Takeda Pharmaceutical Company Limited, 2021, EP [Patent]
- N-heterocyclic compounds as orexin 2 agonists for the treatment of neurological disorders — Takeda Pharmaceutical Company Limited, 2024, EP [Patent]
- An orexin 2 receptor agonist for the treatment of an orexin-mediated disease or disorder — Takeda Pharmaceutical Company Limited, 2022, WO [Patent]
- Orexin 2 Receptor Spiromacrocyclic Agonists — H. Lundbeck A/S, 2026, BR [Patent]
- Peptide derivatives and related uses as orexin agonists — Centessa Pharmaceuticals (Orexia) Limited, 2024, WO [Patent]
- Small-molecule agonists for type-2 orexin receptor — Yanagisawa, Masashi, 2014, US [Patent]
- OX2R compounds — Board of Regents, The University of Texas System, 2019, WO [Patent]
- Prepro-orexin as bioactive peptide, fragments thereof, and variants thereof — Toyama University (National University Corporation), 2023, JP [Patent]
- Dosing of orexin type 2 receptor agonists — Takeda Pharmaceutical Company Limited, 2024, WO [Patent]
- Dosing of orexin type 2 receptor agonists — Takeda Pharmaceutical Company Limited, 2025, WO [Patent]
- World Health Organization — Sleep Disorders — WHO [External]
- National Institutes of Health — Narcolepsy Research — NIH [External]
- European Medicines Agency — CNS Drug Development Guidelines — EMA [External]
- NCBI PubMed — Orexin Receptor Pharmacology Literature — NCBI [External]
- NINDS — Idiopathic Hypersomnia Information — NINDS/NIH [External]
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only. It should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.